Copyright
©The Author(s) 2023.
World J Clin Oncol. Jun 24, 2023; 14(6): 215-226
Published online Jun 24, 2023. doi: 10.5306/wjco.v14.i6.215
Published online Jun 24, 2023. doi: 10.5306/wjco.v14.i6.215
Whole sample, n = 217 | mEHT, n = 89 | No-mEHT, n = 128 | P value1 | ||||
Median | Range | Median | Range | Median | Range | ||
Age (yr) | 67 | 34-89 | 64 | 38-82 | 69 | 34-89 | NS |
Student’s test for proportions | |||||||
M | 122 | 56 | 58 | 65 | 64 | 50 | NS |
F | 95 | 44 | 31 | 35 | 64 | 50 | NS |
Metastatic | 142 | 65 | 70 | 79 | 72 | 56 | 0.004 |
Previous chemotherapy | 136 | 63 | 68 | 76 | 68 | 53 | 0.005 |
Previous Radiotherapy | 10 | 5 | 1 | 1 | 9 | 7 | NS |
Current chemotherapy type | |||||||
Gemcitabine/oxaliplatin | 76 | 35 | 34 | 38 | 42 | 33 | NS |
Gemcitabine | 62 | 29 | 26 | 29 | 36 | 28 | NS |
Gemcitabine/abraxane | 39 | 18 | 9 | 10 | 30 | 23 | NS |
Gemcitabine/5-fluorouracil | 5 | 2 | 4 | 4 | 1 | 1 | NS |
Gemcitabine/cisplatin | 10 | 5 | 2 | 2 | 8 | 6 | NS |
Gemcitabine/Nab-paclitaxel | 2 | 1 | 0 | 0 | 2 | 2 | NS |
FOLFIRINOX | 5 | 2 | 1 | 1 | 4 | 3 | NS |
Other | 10 | 5 | 5 | 6 | 5 | 4 | NS |
None | 8 | 4 | 8 | 9 | 0 | 0 | NS |
Site of metastases | (N = 235) | (N = 132) | (N = 103) | ||||
Liver | 132 | 57 | 70 | 53 | 63 | 61 | NS |
Peritoneum | 55 | 23 | 35 | 27 | 20 | 19 | NS |
Lymph nodes | 37 | 16 | 22 | 17 | 15 | 15 | NS |
Other | 10 | 4 | 5 | 4 | 5 | 5 | NS |
mEHT | n = 87 | no-mEHT | n = 111 | P value | |
PR | 39 | 45 | 27 | 24 | 0.0018 |
SD | 44 | 51 | 50 | 45 | 0.8430 |
PD | 4 | 4 | 34 | 31 | < 0.001 |
- Citation: Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy vs chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol 2023; 14(6): 215-226
- URL: https://www.wjgnet.com/2218-4333/full/v14/i6/215.htm
- DOI: https://dx.doi.org/10.5306/wjco.v14.i6.215